L-Isoleucine (JP14/USP) en es it fr

L-Isoleucine (JP14/USP) Brand names, L-Isoleucine (JP14/USP) Analogs

L-Isoleucine (JP14/USP) Brand Names Mixture

  • No information avaliable

L-Isoleucine (JP14/USP) Chemical_Formula


L-Isoleucine (JP14/USP) RX_link

No information avaliable

L-Isoleucine (JP14/USP) fda sheet

L-Isoleucine (JP14/USP) msds (material safety sheet)

http://www.vinquiry.com/pdf/MSDS/L-Isoleucine MSDS.pdf

L-Isoleucine (JP14/USP) Synthesis Reference

No information avaliable

L-Isoleucine (JP14/USP) Molecular Weight

131.174 g/mol

L-Isoleucine (JP14/USP) Melting Point

168-170 oC

L-Isoleucine (JP14/USP) H2O Solubility

No information avaliable

L-Isoleucine (JP14/USP) State


L-Isoleucine (JP14/USP) LogP


L-Isoleucine (JP14/USP) Dosage Forms

Capsules, powder, tablets

L-Isoleucine (JP14/USP) Indication

The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity.

L-Isoleucine (JP14/USP) Pharmacology

They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert.

L-Isoleucine (JP14/USP) Absorption

Absorbed from the small intestine by a sodium-dependent active-transport process

L-Isoleucine (JP14/USP) side effects and Toxicity

Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs

L-Isoleucine (JP14/USP) Patient Information

No information avaliable

L-Isoleucine (JP14/USP) Organisms Affected

Humans and other mammals